Inhibition of candidalysin production by methoxy-apo-enterobactin from Streptomyces ambofaciens CJD34 as a novel antifungal strategy against Candida albicans
Journal of Microbiology · 2025
DOI: 10.71150/jm.2504019 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Microbiology, 2025. Verfasst von Eui-Seong Kim und 6 weiteren Autor:innen. Beteiligte Einrichtung: Korea Zoonosis Research Institute, Jeonbuk National University, Iksan 54531, Republic of Korea. Hauptthemen laut MEDLINE: Candida albicans, Streptomyces, Antifungal Agents, Fungal Proteins. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Research Foundation of Korea, Ministry of Science and ICT, Jeonbuk National University.
Abstract (Originalsprache)
Opportunistic fungal pathogens, responsible for over 300 million severe cases and 1.5 million deaths annually, pose a serious global health threat, especially in immunocompromised individuals. Among these, Candida albicans is a major cause of both superficial and invasive infections, which can progress to systemic candidiasis. One of the critical factors in C. albicans pathogenicity is the yeast-to-hyphal transition, which enables biofilm formation and promotes tissue invasion through the secretion of candidalysin, a cytolytic peptide toxin encoded by the ECE1 gene. In this study, metabolites produced by Streptomyces ambofaciens CJD34, isolated from soil samples, were screened for antifungal activity. Methoxy-apo-enterobactin (compound 1) was identified as a potential inhibitor of C. albicans virulence. Treatment with compound 1 significantly suppressed ECE1 expression and candidalysin production. In a murine subcutaneous infection model, topical application of compound 1 reduced subcutaneous colonization by C. albicans. Molecular docking analysis suggested that the inhibition of ECE1 expression was not mediated by direct binding to known upstream transcription factors, indicating an indirect mechanism of action. Collectively, these findings highlight compound 1 as a promising antivirulence agent targeting candidalysin-mediated pathogenicity in C. albicans.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Korea Zoonosis Research Institute, Jeonbuk National University, Iksan 54531, Republic of Korea.
- College of Pharmacy, Kyung Hee University, Seoul 02447, Republic of Korea.
- Department of Biomedical and Pharmaceutical Sciences, Graduate School, Kyung Hee University, Seoul 02447, Republic of Korea.
- College of Pharmacy, Yonsei University, Incheon 21983, Republic of Korea.
- Department of Regulatory Science, Graduate School, Kyung Hee University, Seoul 02447, Republic of Korea.
- Institute of Regulatory Innovation through Science, Kyung Hee University, Seoul 02447, Republic of Korea.
Förderung
- National Research Foundation of Korea
- Ministry of Science and ICT
- Jeonbuk National University
Zitieren
APA
Kim, E. S., Jeong, H., Abbas, M., Um, S., Oh, J., Moon, K., & Lee, K. T. (2025). Inhibition of candidalysin production by methoxy-apo-enterobactin from Streptomyces ambofaciens CJD34 as a novel antifungal strategy against Candida albicans. Journal of Microbiology. https://doi.org/10.71150/jm.2504019
Vancouver
Kim ES, Jeong H, Abbas M, Um S, Oh J, Moon K, et al. Inhibition of candidalysin production by methoxy-apo-enterobactin from Streptomyces ambofaciens CJD34 as a novel antifungal strategy against Candida albicans. Journal of Microbiology. 2025. doi:10.71150/jm.2504019
BibTeX
@article{Kim2025,
author = {Kim, Eui-Seong and Jeong, Hyeongju and Abbas, Mustansir and Um, Soohyun and Oh, Juntack and Moon, Kyuho and Lee, Kyung-Tae},
title = {Inhibition of candidalysin production by methoxy-apo-enterobactin from Streptomyces ambofaciens CJD34 as a novel antifungal strategy against Candida albicans},
journal = {Journal of Microbiology},
year = {2025},
doi = {10.71150/jm.2504019}
}
EUVIMED